Vir Biotechnology, Inc. (VIR)
| Previous close | 8.10 |
| Open | 8.10 |
| Bid | 8.21 x 100 |
| Ask | 8.34 x 100 |
| Day's range | 8.08 - 8.28 |
| 52-week range | 7.72 - 27.48 |
| Volume | |
| Avg. volume | 1,077,337 |
| Market cap | 1.125B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.59 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.29 |
Business WireVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
SAN FRANCISCO, April 18, 2024--Vir Biotechnology, Inc. ("Vir" or "the Company", Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the "Board") at its upcoming annual meeting of stockholders on May 29, 2024 (the "Annual Meeting"). If elected, each of Drs. Bischofberger and Farid will join the Board on such date.
Business WireVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO, April 11, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024.
GuruFocus.comVir Biotechnology Inc CEO Backer De Sells 72,995 Shares
Vir Biotechnology Inc (NASDAQ:VIR), a company focused on the research and development of treatments for serious infectious diseases, has reported an insider sell according to a recent SEC filing.
